Clinical manifestations of homozygote allele carriers in Huntington disease

Authors:
  • SMSaul-Indra Martinez-Horta
    Saul-Indra Martinez-Horta
  • FSFrederic Sampedro Santalo
    Frederic Sampedro Santalo
  • ADAsunción Martínez Descalls
    Asunción Martínez Descalls
  • SCSara Calvo
    Sara Calvo
  • CGCecilia Gil-Polo
    Cecilia Gil-Polo
  • IMIgnacio Muñoz
    Ignacio Muñoz
  • KLKatia Llano
    Katia Llano
  • NMNatividad Mariscal
    Natividad Mariscal
  • DDDolores Diaz
    Dolores Diaz
  • AGAranzazu Gutierrez
    Aranzazu Gutierrez
  • LALaura Aguado
    Laura Aguado

Abstract
Objective Because patients homozygous for Huntington disease (HD) receive the gain-of-function mutation in a double dose, one would expect a more toxic effect in homozygotes than in heterozygotes. Our aim was to investigate the phenotypic differences between homozygotes with both alleles ≥36 CAG repeats and heterozygotes with 1 allele ≥36 CAG repeats. Methods This was an international, longitudinal, case-control study (European Huntington9s Disease Network Registry database). Baseline and longitudinal total functional capacity, motor, cognitive, and behavioral scores of the Unified Huntington9s Disease Rating Scale (UHDRS) were compared between homozygotes and heterozygotes. Four-year follow-up data were analyzed using longitudinal mixed-effects models. To estimate the association of age at onset with the length of the shorter and larger allele in homozygotes and heterozygotes, regression analysis was applied. Results Of 10,921 participants with HD (5,777 female [52.9%] and 5,138 male [47.0%]) with a mean age of 55.1 ± 14.1 years, 28 homozygotes (0.3%) and 10,893 (99.7%) heterozygotes were identified. After correcting for multiple comparisons, homozygotes and heterozygotes had similar age at onset and UHDRS scores and disease progression. In the multivariate linear regression analysis, the longer allele was the most contributing factor to decreased age at HD onset in the homozygotes (p < 0.0001) and heterozygotes (p < 0.0001). Conclusions CAG repeat expansion on both alleles of the HTT gene is infrequent. Age at onset, HD phenotype, and disease progression do not significantly differ between homozygotes and heterozygotes, indicating similar effect on the mutant protein. Classification of evidence This study provides Class II evidence that age at onset, the motor phenotype and rate of motor decline, and symptoms and signs progression is similar in homozygotes compared to heterozygotes.

This publication has 27 references indexed in Scilit: